FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy

Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer

(2013) Megumi Ishiguro et al.   BMC CANCER

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer

(2013) Kyung-Hun Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis

(2013) Zhi Peng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

(2013) Beatrice Mohelnikova-Duchonova et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

(2013) F. Lin et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

(2013) K E Caudle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy

(2013) Ming-Yii Huang et al.   JOURNAL OF SURGICAL ONCOLOGY

Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues

(2013) Beatrice Mohelnikova-Duchonova et al.   PANCREAS

Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?

(2013) Beatrice Mohelnikova-Duchonova et al.   PANCREATOLOGY

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

(2013) Elena De Mattia et al.   Pharmacogenetics and Genomics

Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis

(2013) Huizhe Wu et al.   PHARMACOGENOMICS

Polymorphic Expression of UDP-Glucuronosyltransferase UGTlA Gene in Human Colorectal Cancer

(2013) Min Wang et al.   PLoS One

SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer

(2013) Liu Huang et al.   PLoS One

Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2

(2013) J. A. Sprowl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatic arterial infusion in colorectal carcinoma: is anatomical targeting still relevant in an era of molecularly targeted therapy?

(2012) Bohuslav Melichar   BIOMEDICAL PAPERS-OLOMOUC

Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer

(2012) Sotaro Sadahiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53

(2012) E. Gabriela Chiorean et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy

(2012) Lee Cheng Phua et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacogenomics Knowledge for Personalized Medicine

(2012) M Whirl-Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer

(2012) Sae-Won Han et al.   INTERNATIONAL JOURNAL OF CANCER

The role of ABC transporters in progression and clinical outcome of colorectal cancer

(2012) I. Hlavata et al.   MUTAGENESIS

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis

(2012) Barbara Anne Jennings et al.   Pharmacogenetics and Genomics

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis

(2012) Mafalda M Dias et al.   PHARMACOGENOMICS

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

(2011) E Marcuello et al.   BRITISH JOURNAL OF CANCER

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study

(2011) Maria Teresa Di Martino et al.   CANCER BIOLOGY & THERAPY

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer Patients

(2011) Toshiaki Watanabe et al.   DISEASES OF THE COLON & RECTUM

Predictive Value of Expression of ERCC 1 and GST-p for 5-Fluorouracil/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer

(2011) Eiji Noda et al.   HEPATO-GASTROENTEROLOGY

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials

(2011) P P Grimminger et al.   PHARMACOGENOMICS JOURNAL

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11

(2010) M. Jason Hatfield et al.   BIOCHEMICAL PHARMACOLOGY

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

(2010) Howard L. McLeod et al.   JOURNAL OF CLINICAL ONCOLOGY

PharmGKB summary: fluoropyrimidine pathways

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy

(2010) Ming-Yii Huang et al.   Pharmacogenetics and Genomics

Irinotecan pharmacogenomics

(2010) Sharon Marsh et al.   PHARMACOGENOMICS

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

(2010) B Glimelius et al.   PHARMACOGENOMICS JOURNAL

Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy

(2009) Dirk Theile et al.   BIOCHEMICAL PHARMACOLOGY

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

(2009) Kimie Sai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

(2009) Jiun-I. Lai et al.   CANCER SCIENCE

Influence ofGSTP1I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

(2009) Yen-Chung Chen et al.   CANCER SCIENCE

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study

(2009) Miriam Koopman et al.   EUROPEAN JOURNAL OF CANCER

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

(2009) Miriam Koopman et al.   EUROPEAN JOURNAL OF CANCER

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy

(2009) Eva Martinez-Balibrea et al.   INTERNATIONAL JOURNAL OF CANCER

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

(2009) R. Humeniuk et al.   MOLECULAR CANCER THERAPEUTICS

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum pathway

(2009) Sharon Marsh et al.   Pharmacogenetics and Genomics

Genetic polymorphisms inGSTgenes and survival of colorectal cancer patients treated with chemotherapy

(2009) Silvia Funke et al.   PHARMACOGENOMICS

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy

(2008) R. Soong et al.   ANNALS OF ONCOLOGY

ERCC22251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study

(2008) Ming-Yii Huang et al.   BMC CANCER

ERCC1codon 118 C→T polymorphism associated withERCC1expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma

(2008) Peter Mu-Hsin Chang et al.   CANCER SCIENCE

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

(2008) Ji-Youn Han et al.   LUNG CANCER

ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines

(2008) Wolfgang Hagmann et al.   PANCREATOLOGY